Comparison · NCT01751724-05ff2f95
Caffeine Arm vs Placebo Arm: Number of Infants With Severe Retinopathy of Prematurity
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Caffeine Arm vs Placebo Arm: Number of Infants With Severe Retinopathy of Prematurity. Trial comparisons, record NCT01751724-05ff2f95. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01751724-05ff2f95
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0732 | 0.0252 | 0.194 | wilson | |
| Risk in group 2 | 0.119 | 0.0519 | 0.25 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0459 | -0.185 | 0.0926 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.615 | 0.157 | 2.41 | log | |
| Odds ratio, group 1 over group 2 | 0.584 | 0.13 | 2.62 | log | |
| Number needed to treat, for one fewer participant with the outcome on Caffeine Arm than on Placebo Arm | 21.8 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Caffeine Arm | Subjects randomized to this arm will receive blinded Caffeine citrate.~Caffeine citrate: Enrolled subjects will be randomized to receive a study drug consisting of either blinded Caffeine citrate.~Randomization and study drug preparation will be done by the NICU pharmacy. Investigators and clinicians will be blinded to the assigned drug.~After randomization, an initial loading dose of 20 mg/Kg of study drug will be followed by a 5 mg/Kg/day maintenance dose. The assigned study drug will be administered intravenous or orally as determined by the clinical team.~Infants will continue to receive the study drug until 12 hours prior to the first elective extubation. | 3 | 41 | OG000 |
| Group 2 | Placebo Arm | Subjects randomized to this arm will receive blinded Placebo (equivalent volume of normal saline).~Normal saline: Enrolled subjects will be randomized to receive a study drug consisting of blinded Placebo (equivalent volume of normal saline).~Randomization and study drug preparation will be done by the NICU pharmacy. Investigators and clinicians will be blinded to the assigned drug.~After randomization, an initial loading dose of 20 mg/Kg of study drug will be followed by a 5 mg/Kg/day maintenance dose. The assigned study drug will be administered intravenous or orally as determined by the clinical team.~Infants will continue to receive the study drug until 12 hours prior to the first elective extubation. | 5 | 42 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- OTHER_PRE_SPECIFIED
- Title
- Number of Infants With Severe Retinopathy of Prematurity
- Description
- Severe retinopathy of prematurity defined as stage 3 or higher
- Time frame
- From enrollment until 36 weeks postmenstrual age, discharge or death
- Population
Source ClinicalTrials.gov
Trial
- Title
- Caffeine to Reduce Mechanical Ventilation in Preterm Infants
- NCT number
- NCT01751724
- Phases
- NA
- Conditions
- Prematurity, Apnea, Respiratory Failure
- Interventions
- Caffeine citrate, Normal saline
- Lead sponsor
- University of Miami
- Results first posted
- 2017-06-19
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01751724?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01751724-05ff2f95